Allarity Therapeutics A/S: Financial statements 2012
CVR: 28106351
Source: annual report 2012, Danish Business Authority
01/01/2012 – 31/12/2012
Allarity Therapeutics A/S (CVR 28106351) has filed annual accounts for 2012. In 2012, the company reported revenue of DKK 3,943,474 and a net result of DKK -2,768,795. The profit margin was -70.2%. Equity in the 2012 report amounted to DKK 4,461,672. The solvency ratio was 75.3%.
- Revenue
- DKK 3,943,474
- Gross Profit
- DKK 565,804
- Profit/Loss
- DKK -2,768,795
- Equity
- DKK 4,461,672
- Total Assets
- DKK 5,926,174
Official annual report
Keep an eye on Allarity Therapeutics A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2012
As of June 27, 2012, Peter Buhl has joined the board of directors of Allarity Therapeutics A/S.
As of June 27, 2012, Jørgen Søberg Petersen is registered as chairman of Allarity Therapeutics A/S.
As of June 27, 2012, Frank Knudsen has stepped down as chairman of Allarity Therapeutics A/S.
As of March 1, 2012, Peter Buhl is registered as adm. dir. of Allarity Therapeutics A/S.
As of March 1, 2012, Jon Askaa has stepped down as adm. dir. of Allarity Therapeutics A/S.
About Allarity Therapeutics A/S
Allarity Therapeutics A/S was a Danish company of the type Aktieselskab based in Hørsholm, founded in 2004. The company has been dissolved on 16 October 2025. The company was registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named ONCOLOGY VENTURE A/S and MEDICAL PROGNOSIS INSTITUTE A/S. The company has 6 employees (2021). In 2024, the company reported a gross profit of DKK -81,000 and a net result of DKK -83,000 compared with DKK -406,000 the year before. Equity in the 2024 report amounted to DKK 0.
